These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Hizawa N Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659 [TBL] [Abstract][Full Text] [Related]
27. Trelegy Ellipta--a three-drug inhaler for COPD. Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467 [No Abstract] [Full Text] [Related]
28. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
29. Response. Rho J; Ho N; Prasad V Chest; 2015 Jul; 148(1):e31-e32. PubMed ID: 26149564 [No Abstract] [Full Text] [Related]
31. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T; Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629 [TBL] [Abstract][Full Text] [Related]
32. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey. Ding B; Small M Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116 [TBL] [Abstract][Full Text] [Related]
33. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905 [TBL] [Abstract][Full Text] [Related]
39. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930 [TBL] [Abstract][Full Text] [Related]
40. Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease. Minakata Y; Morishita Y; Ichikawa T; Akamatsu K; Hirano T; Nakanishi M; Matsunaga K; Ichinose M Int J Chron Obstruct Pulmon Dis; 2015; 10():1275-82. PubMed ID: 26170656 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]